This well-conducted review assessed the effects of sirolimus and paclitaxel drug-eluting stents (DES) for coronary disease. The authors concluded that DES are effective in reducing restenosis and revascularisation in patients with and without diabetes; sirolimus appeared more effective than paclitaxel in non-diabetics, whereas both had similar effects in diabetics. Given the reliance on indirect evidence the findings should be interpreted with some caution.
Participants included in the review
Studies of people with stable or unstable angina and signs of myocardial ischaemia, with a new target lesion in a native coronary artery, were eligible for inclusion. One study was on people with diabetes, whereas in the other studies those with diabetes represented a subgroup of participants. Overall, 25% of the included participants had diabetes, between 28% and 42% had a previous myocardial infarction (MI), and others had hypertension, dyslipidaemia or were smokers. All of the included studies excluded people with a recent MI, a stenosis of at least 50% in the left main coronary artery, or those with heart failure. The majority of the participants were males over the age of 60 years.
Outcomes assessed in the review
The outcomes of interest were in-stent restenosis (50% or greater confirmed by angiography or ultrasound), in-segment restenosis (50% or greater confirmed by angiography or ultrasound), target lesion revascularisation (coronary artery bypass graft, repeat percutaneous coronary intervention at or adjacent to stent site) and major adverse cardiac events (Qwave and non Q-wave MI, revascularisation or death).
How were decisions on the relevance of primary studies made?
Two reviewers independently assessed papers for inclusion. Any discrepancies were resolved through discussion with a third reviewer. Two reviewers independently assessed studies for quality. Any disagreements were resolved through discussion with a third reviewer. Factors considered were adequacy of allocation concealment to treatment groups and blinding of the care providers and research staff assessing outcomes.
Assessment of study quality

Data extraction
Two reviewers independently extracted the data. Any disagreements were resolved through discussion with a third reviewer. Authors from the included studies were contacted and asked to check the extracted data and, where necessary, provide additional data.
Incidence rates were calculated in individual studies by dividing the number of events by the number of person-years at follow-up. Incidence rate ratios (IRRs) were calculated by dividing the incidence in the DES group by the incidence in the BMS group. Studies with no outcome event in either group were excluded. Where studies had events in only one group, 0.5 was added to all cells in the analysis.
Methods of synthesis
How were the studies combined? Pooled IRRs with 95% confidence intervals (CIs) were calculated separately for all participants and for those with or without diabetes using crude and adjusted indirect fixed-effect meta-analyses. A random-effects meta-regression model was used to calculate the ratio of IRRs (RIRR) between the two DES types. Numbers-needed-to-treat to prevent one event were calculated, along with 95% CIs. Funnel plots were used to assess publication bias.
How were differences between studies investigated? I-squared statistics, together with standard tests, were used to assess heterogeneity. Sensitivity analyses were carried out using a random-effects model. In addition, the data were reanalysed to correct for angiographic-driven revascularisation.
Results of the review
Ten RCTs (4,513 participants: 1,146 with diabetes and 3,367 without) were included; 6 studies were of sirolimus DES and 4 studies were of paclitaxel DES. In two of the included studies randomisation was stratified according to diabetic status.
The trials were of a high methodological quality.
Compared with BMS, DES were associated with substantial reductions in the risk of restenosis. This reduction was greater with sirolimus-than with paclitaxel-eluting stents (in-stent restenosis, RIRR 0.35, 95% CI: 0.21, 0.57; insegment restenosis, RIRR 0.68, 95% CI: 0.45, 1.01).
Sirolimus-eluting stents were statistically superior to paclitaxel-eluting in patients without diabetes with regard to instent restenosis (RIRR 0.21, 95% CI: 0.10, 0.48, p<0.001), in-segment restenosis (RIRR 0.47, 95% CI: 0.24, 0.92, p=0.027), target lesion revascularisation (RIRR 0.54, 95% CI: 0.30, 0.99, p=0.045) and major adverse events (RIRR 0.46, 95% CI: 0.26, 0.83, p=0.010). No significant differences between the two different DES were identified for any of the end points in patients with diabetes. A significant difference between patients with and without diabetes was identified using meta-regression (tests for interaction: p=0.036 and p=0.016 for in-stent restenosis and in-segment restenosis, respectively).
